Australia
· Delayed Price · Currency is AUD Neurizon Therapeutics Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally.
The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases.
Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.
The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.
Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Michael Thurn |
Contact Details
Address: 96-100 Albert Road Melbourne, 3205 Australia | |
| Phone | 61 3 9692 7222 |
| Website | neurizon.com |
Stock Details
| Ticker Symbol | NUZ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Thurn Ph.D. | MD, Chief Executive Officer and Director |
| John Clark | Chief Operating Officer |
| Fiona Milner | General Manager of Epichem Pty Ltd |
| Lidija Damjanovic | Head of Marketing and Corporate Affairs |
| Dr. Gary Pitt | Head of Chemistry |
| Dr. James Rixson | Head of Production |
| Dr. Herbert Brinkman | Head of Manufacturing |
| Stefan Ross | Company Secretary |